Literature DB >> 27229111

Physiologic effects of continuous-flow left ventricular assist devices.

Aaron H Healy1, Stephen H McKellar1, Stavros G Drakos2, Antigoni Koliopoulou1, Josef Stehlik2, Craig H Selzman3.   

Abstract

BACKGROUND: Within the past 10 years, continuous-flow left ventricular assist devices (LVADs) have replaced pulsatile-flow LVADs as the standard of care for both destination therapy and bridging patients to heart transplantation. Despite the rapid clinical adoption of continuous-flow LVADs, an understanding of the effects of continuous-flow physiology, as opposed to more natural pulsatile-flow physiology, is still evolving.
MATERIALS AND METHODS: A thorough review of the relevant scientific literature regarding the physiological and clinical effects of continuous-flow physiology was performed. These effects were analyzed on an organ system basis and include an evaluation of the cardiovascular, respiratory, hematologic, gastrointestinal, renal, hepatic, neurologic, immunologic, and endocrine systems.
RESULTS: Continuous-flow physiology is, generally speaking, well tolerated over the long term. However, several changes are manifest at the organ system level. Although many of these changes are without appreciable clinical significance, other changes, such as an increased rate of gastrointestinal bleeding, appear to be associated with continuous-flow physiology.
CONCLUSIONS: Continuous-flow LVADs confer a significant advantage over their pulsatile-flow counterparts with regard to size and durability. From a physiological standpoint, continuous-flow physiology has limited clinical effects at the organ system level. Although improved over previous generations, challenges with this technology remain. Approaching these problems with a combination of clinical and engineering solutions may be needed to achieve continued progression in the field of durable mechanical circulatory support.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiac surgery; Heart failure; Left ventricular assist device; Mechanical circulatory support; Physiology

Mesh:

Year:  2016        PMID: 27229111      PMCID: PMC4886545          DOI: 10.1016/j.jss.2016.01.015

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  78 in total

1.  HeartMate VE LVAS design enhancements and its impact on device reliability.

Authors:  R D Dowling; S J Park; F D Pagani; A J Tector; Y Naka; T B Icenogle; V L Poirier; O H Frazier
Journal:  Eur J Cardiothorac Surg       Date:  2004-06       Impact factor: 4.191

2.  Left ventricular bypass pump for cardiac assistance. Clinical experience.

Authors:  M E DeBakey
Journal:  Am J Cardiol       Date:  1971-01       Impact factor: 2.778

3.  Adrenocortical hormone concentrations in children during cardiopulmonary bypass with and without pulsatile flow.

Authors:  E M Pollock; J C Pollock; M P Jamieson; G S Beastall; C Wright; B Torsney; L R McNicol
Journal:  Br J Anaesth       Date:  1988-04       Impact factor: 9.166

4.  Cardiac disuse atrophy during LVAD pumping.

Authors:  M Kinoshita; H Takano; Y Taenaka; H Mori; S Takaichi; H Noda; E Tatsumi; A Yagura; H Sekii; T Akutsu
Journal:  ASAIO Trans       Date:  1988 Jul-Sep

5.  Comparative studies of pulsatile and nonpulsatile flow during cardiopulmonary bypass. II. The effects on adrenal secretion of cortisol.

Authors:  K M Taylor; G S Wright; J M Reid; W H Bain; P K Caves; M S Walker; J K Grant
Journal:  J Thorac Cardiovasc Surg       Date:  1978-04       Impact factor: 5.209

6.  Adrenocortical hormone levels during cardiopulmonary bypass with and without pulsatile flow.

Authors:  K Kono; D M Philbin; C H Coggins; E E Slater; A Triantafillou; F H Levine; M J Buckley
Journal:  J Thorac Cardiovasc Surg       Date:  1983-01       Impact factor: 5.209

7.  Left ventricular pressure and volume unloading during pulsatile versus nonpulsatile left ventricular assist device support.

Authors:  Stefan Klotz; Mario C Deng; Joerg Stypmann; Juergen Roetker; Markus J Wilhelm; Dieter Hammel; Hans H Scheld; Christof Schmid
Journal:  Ann Thorac Surg       Date:  2004-01       Impact factor: 4.330

8.  Clinical use of the total artificial heart.

Authors:  W C DeVries; J L Anderson; L D Joyce; F L Anderson; E H Hammond; R K Jarvik; W J Kolff
Journal:  N Engl J Med       Date:  1984-02-02       Impact factor: 91.245

9.  Doppler microembolic load predicts risk of thromboembolic complications in Novacor patients.

Authors:  Darius G Nabavi; Joerg Stockmann; Christof Schmid; Michael Schneider; Dieter Hammel; Hans H Scheld; E Bernd Ringelstein
Journal:  J Thorac Cardiovasc Surg       Date:  2003-07       Impact factor: 5.209

10.  Continuous axial-flow left ventricular assist device (Jarvik 2000) maintains kidney and liver perfusion for up to 6 months.

Authors:  George V Letsou; Timothy J Myers; Igor D Gregoric; Reynolds Delgado; Nyma Shah; Kimberly Robertson; Branislav Radovancevic; O H Frazier
Journal:  Ann Thorac Surg       Date:  2003-10       Impact factor: 4.330

View more
  3 in total

1.  Sympathetic Markers are Different Between Clinical Responders and Nonresponders After Left Ventricular Assist Device Implantation.

Authors:  Quin E Denfeld; Christopher S Lee; William R Woodward; Shirin O Hiatt; James O Mudd; Beth A Habecker
Journal:  J Cardiovasc Nurs       Date:  2019 Jul/Aug       Impact factor: 2.083

Review 2.  The ongoing quest for the first total artificial heart as destination therapy.

Authors:  Annemijn Vis; Maziar Arfaee; Husain Khambati; Mark S Slaughter; Jan F Gummert; Johannes T B Overvelde; Jolanda Kluin
Journal:  Nat Rev Cardiol       Date:  2022-06-06       Impact factor: 32.419

3.  A Multi-Domain Simulation Study of a Pulsatile-Flow Pump Device for Heart Failure With Preserved Ejection Fraction.

Authors:  Caglar Ozturk; Luca Rosalia; Ellen T Roche
Journal:  Front Physiol       Date:  2022-01-25       Impact factor: 4.566

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.